HPLC method development for determination of metoprolol, telmisartan and cilnidipine simultaneously using response surface design
Article Sidebar
-
HPLC, Metoprolol, Cilnidipine, Telmisartan, Optimum Flow Rate, Chromatographic Conditions
Abstract
The development of an HPLC method for determination of Metoprolol, Telmisartan and Cilnidipine simultaneously in additional dosage was not published or reported up till date. The main aim of our study was to design a simultaneous and multiple response optimizations using the Derringer’s desirability function in order to estimate Metoprolol, Telmisartan and Cilnidipine in pharmaceutical and bulk drug dosage form by HPLC method with experiment central compositive design (CCD) protocol for the quantitative methods analysis and also for validation of the procedure that is developed as per ICH regulations. An innovative RP-HPLC method had been designed for the estimation of Metoprolol, Telmisartan and Cilnidipine simultaneously in formulation using central composite design. Three factors were investigated and determined as significant when compared to the interaction and quadratic effect of the samples that CCD along with the response of the surface methodology. The developed method produced a good resolution of the drugs with a very short run time of 7.5 min. It was also validated according to ICH guidelines. It was recognized as novel and simple method that is accurate and cost-effective. So the proposed method fits best in the assaying routine of Metoprolol, Telmisartan and Cilnidipine in any formulations produced by quality control laboratories.
Full text article
References
Bakheit, A. H., et al. 2015. Telmisartan. In In Profiles of Drug Substances, Excipients and Related Methodology. Academic Press. Vol: 40, Pages: 371-429.
Beg, Q. K., et al. 2003. Statistical media optimization and alkaline protease production from Bacillus mojavensis in a bioreactor. Process Biochemistry, 39(2):203–209.
Desai, D., et al. 2016. HPTLC method development and validation of cilnidipine and metoprolol succinate in combined dosage form. Pharmaceutical Methods, 7(1):28–34.
Ermer, J., John, J. H. 2005. Method validation in pharmaceutical analysis. Wiley. Pages: 418 .
Gad, S. C. 2014. United States Pharmacopoeia (USP). Encyclopedia of Toxicology, pages 881–882.
Haripriya, M., et al. 2013. Development and validation of UV spectrophotometric method for the simultaneous estimation of Cilnidipine and telmisartan in tablet dosage form utilising simultaneous equation and absorbance ratio method. Int J of Pharm and Bio Sci, 3(1):343–348.
ICH 2003. ICH topic Q1A (R2) - stability testing of new drug substances and products. . Pages: 20 [Accessed On August, 2003].
ICH Expert Working Group 2003. ICH guideline Q1A (R2) stability testing of new drug substances and products. In Int Conf on Harm, 4:1–24.
Kardani, K., et al. 2013. RP-HPLC method development and validation of gallic acid in polyherbal tablet formulation. Journal of Applied Pharmaceutical Science, 3(5):37–42.
Kim, J. K., et al. 2006. Framework for analyzing critical incident management systems (CIMS). Proceedings of the 39th Annual Hawaii International Conference on System Sciences, 4:79–79.
Lundstedt, T., et al. 1998. Experimental design and optimization. Chemometrics and Intelligent Laboratory Systems, 42(1-2):3–40.
Parajo, J. C., et al. 1992. Empirical modeling of eucalyptus wood processing. Bioprocess Engineering, 8(3-4):129–136.
Rupareliya, R. H., et al. 2013. Stability indicating simultaneous validation of telmisartan and cilnidipine with forced degradation behavior study by RP-UPLC in tablet dosage form. ISRN Chromatography, 2013(1):1–6.
Santosh, R., et al. 2015. Development and validation of stability-indicating HPTLC method for simultaneous determination of Telmisartan and Cilnidipine in combined tablet dosage form. Int J of Pharm Sci and Drug Res, 7(6):478–483.
Siripuram, P. K., et al. 2010. Formulation and characterization of floating gelucire matrices of metoprolol succinate. Dis Tech, 17(3):34–39.
Uneyama, H., et al. 1999. Cilnidipine: Preclinical profile and clinical evaluation. Cardiovascular drug reviews, 17(4):341–357.
Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.